Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Iovance Biotherapeutics Inc.
Headquarters: San Carlos, CA, United States of America
Website: http://www.iovance.com
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Frederick G. Vogt, PhD
Number Of Employees: 838
Enterprise Value: $1,879,572,800
PE Ratio: -2.8
Exchange/Ticker 1: NASDAQ:IOVA
Exchange/Ticker 2: N/A
Latest Market Cap: $1,190,193,536
BioCentury | Mar 29, 2025
Management Tracks
Aurion names Arnaud Lacoste CEO
Plus: David de Vries named CEO of Tr1x, and updates from Crispr, Pacbio, Alvotech and Tscan
BioCentury | Jan 14, 2025
Deals
JPM ushers in flurry of biotech deals, headlined by J&J’s Intra-cellular buy
BioCentury’s Deals Report surveys deals by GSK, Idrx, Lilly, Scorpion, Lantheus, Telix, Gilead, Leo, CBC Group and more
BioCentury | Jan 13, 2025
Deals
JPM deal buzz & Rep. Auchincloss’ take on biopharma
J&J’s nearly $15B neuro buy kicks off biotech meeting. Plus: Washington insights and 2024’s key FDA approvals
BioCentury | Jan 6, 2025
Regulation
2024 Approvals: Where are the new modalities?
Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development
BioCentury | Nov 20, 2024
Product Development
Biotechs now match pharma for FDA approvals
Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
BioCentury | Sep 10, 2024
Management Tracks
Vir names Jason O’Byrne CFO
Plus: Maslowski to become CEO of Forge as Miller steps down, and updates from Sofinnova Partners, Abingworth, PATH and more
BioCentury | Aug 3, 2024
Data Byte
Seven more PDUFA dates in August
After starting the month with two approvals, FDA’s remaining decisions include Gilead’s seladelpar, Regeneron’s BCMAxCD3 bispecific
BioCentury | Mar 26, 2024
Management Tracks
Former BioMarin CEO Bienaimé named chair of Owkin
Plus: Dyne shares slip with CEO departing, and updates from Ardelyx and ProKidney
BioCentury | Feb 24, 2024
Finance
Public equity report: Iovance, Ocular Therapeutix cash in on catalysts
In an otherwise slow week for public financings
BioCentury | Feb 21, 2024
Product Development
Safer CAR Ts & world’s first TIL: BioCentury’s latest podcast
Plus: translational highlights and Sarepta’s path to a gene therapy approval
Items per page:
1 - 10 of 69